Abstract. Advanced malignant melanoma is characterized by rapid development, poor prognosis and insensitivity to chemoradiotherapy. Immunotherapy has become one of the primary clinical treatments for malignant melanomas. In recent decades, identifying specific tumour antigens and the enhanced immunoactivity of tumour vaccines has become critical for engineering successful tumour vaccines. As a widely used vaccine carrier, heat shock protein 70 (HSP70) clearly increases the immunogenicity of tumour antigens, such as melanoma-associated antigen A1 (MAGEA1). Based on previous studies, gas-filled ultrasound microbubbles (MBs) were engineered to carry an HSP70-MAGEA1 fusion protein (FP). Following subcutaneous injection around the lymphatic nodes the FP was directly released into the lymph nodes under ultrasonic imaging. The results indicated that the microbubbles enhanced the immunoactivity of FPs more effectively than HSP70-MAGEA1 fusion alone. Additionally, HSP70-MAGEA1 delivered via microbubbles clearly inhibited and delayed the growth of MAGEA1-expressing B16 melanomas in mice and improved the survival times of these animals compared with the fusion protein alone. The results of the present study demonstrated that controlled MBs enhance the immunoactivity of FPs and also highlights novel, potential vaccine carriers and a new strategy for engineering controllable tumour vaccine designs.
Introduction
Tumour vaccines have become the hot spots of anticancer immunotherapy in recent decades, and tumour-specific antigens (TSAs) have been used to induce specific cellular and humoural immune responses to inhibit tumour occurrence and development. TSAs can stimulate specific immune responses and are the main components in tumour vaccines. As the first discovered TSA, Melanoma-associated antigen A1 (MAGEA1) is expressed in most tumours, including the testes and placenta (1) (2) (3) . MAGEA1 be processed and presented by human leukocyte antigen (HLA) class I molecules on cancer cells, and MAGEA1-expressing cancer cells can be rejected by host cytotoxic T lymphocytes (CTLs) (4, 5) . Tumour vaccines based on MAGEA1 have been used in patients with a variety of tumours, but most of these vaccines do not exhibit particularly significant clinical effects on cancer (6) (7) (8) (9) (10) . Therefore, it is imperative to explore more effective TSA-based tumour vaccines.
As a molecular chaperone, heat shock protein 70 (HSP70) participates in processing and presenting tumour antigens, and HSP70 fused with TSA can significantly enhance cellular and humoural immune responses against cancer cells (11) . Moreover, previous studies have shown that the HSP70-MAGEA1 fusion protein can stimulate MAGEA1-specific antitumour immunity (11) (12) (13) . However,
Gas-filled ultrasound microbubbles enhance the immunoactivity of the HSP70-MAGEA1 fusion protein against MAGEA1-expressing tumours
the immunoactivity of HSP70 fusion proteins needs further improvement for their clinical application. In recent years, gas-filled microbubbles (MBs) have been used in the clinic as intravenously administered ultrasound-based contrast agents (14, 15) due to their high acoustic impedance mismatch between gases and blood (16, 17) . The delivery of DNA/RNA/protein in target cells by the application of ultrasound, a process known as sonoporation, has successfully been applied (18, 19) and demonstrated as a good candidate for lipid-based TSA delivery. Gas-filled ultrasound microbubbles can transport drugs or genes across cell membranes and vessel walls and are considered effective transport carriers in vivo. Moreover, gas-filled ultrasound microbubbles are efficiently phagocytosed and presented bydendritic cells (DC) and activate stronger immune responses (20, 21) .
In the present study, we used gas-filled ultrasound microbubbles as carriers for the controllable release of HSP70-MAGEA1 fusion proteins at a specific location and evaluated the immunoactivity of antitumours to explore a new strategy for future tumour immunotherapy.
Materials and methods
Animals and cell lines. C57BL/6 mice (8 weeks old) were provided from the Laboratory Animal Center of the Fourth Military Medical University and fed in a specific pathogen-free (SPF) animal house. All experiments were conducted according to the guidelines for the Care and Use of Laboratory Animals and approved by the Animal Ethical Committee of the Fourth Military Medical University. B16 cell lines overexpressing MAGEA1 (B16-MAGEA1) were previously established (22) .
Preparation and identification of gas-filled ultrasound microbubbles (MBs).
The MBs were prepared as previously reported (23) . Briefly, a mixture of the nonionic surfactant Span 60 (3 wt%), Tween 80 (5 wt%), and polyethylene glycol (PEG; 3 wt%) with different polymerization degrees were sonicated in PBS solution using a high-intensity ultrasonic processor (VCX-750; Sonix, USA) for 1 min at 400 W in the presence of sulfur hexafluoride (SF 6 ) gas. Then, the mixture was incubated in a separating funnel for 30 min, and the middle layer, comprising the microbubbles, was separated and washed with PBS. To prepare the fusion protein-loaded microbubbles (MB-FP), 200 µl of HSP70-MAGEA1 was incubated with 1 ml of MBs for 10 min at 4˚C, and the fusion proteins were adsorbed onto the MBs via electrostatic adsorption self-assembly. Unloaded protein was removed after three centrifugal washes with PBS buffer solution. After washing, the size distribution of the protein-loaded microbubbles was measured using a Coulter counter (Multisizer III, Beckman-Coulter, Pasadena, CA, USA) (15) . After extraction, the protein concentration was measured using the Bradford method. The prepared gas-filled ultrasound microbubbles were stored in sealed glass vials under a headspace filled with SF 6 gas at 4˚C.
Immunization regime. C57BL/6 mice were subcutaneously (s.c.) immunized in the foreleg with 10 µg/100 µl/mouse gas-filled ultrasound microbubbles carrying HSP70-MAGEA1 fusion protein (MB-FP group), and HSP70-MAGEA1 fusion protein alone (FP group) or gas-filled ultrasound microbubbles (MB group) alone were used as controls. After administration, the MBs were destroyed near the inguinal lymph nodes with a mechanical index (MI=0.7). Three administrations at one-week intervals were performed, and the sera and spleen were collected for experiments at two weeks after the last injection.
Immunoblotting analysis. The lymph nodes from vaccinated mice were used for immunoblotting to detect HSP70 and MAGEA1 proteins. The total proteins were extracted from the spleens using RIPA buffer, and the cell debris was removed by centrifugation at 12,000 x g for 20 min at 4˚C. After quantification, 10-50 µg/lane of the spleen proteins were separated by SDS-PAGE. The MAGEA1 and HSP70 proteins were detected using anti-human MAGEA1 and anti-HSP70 (both Abcam, Cambridge, UK) antibodies, respectively.
IFNγ enzyme-linked immunosorbent spot (ELISpot) assay.
The mouse IFNγ ELISpot assay was performed as previously described (22) in PVDF-bottomed 96-well plates (Millipore, USA) using a commercial kit (Diaclone, France). Briefly, the plates were covered with an anti-IFNγ antibody overnight at 4˚C and blocked with 5% non-fat skimmed milk. The splenocytes (2x10 5 cells/well) were then inoculated together with the indicated number of lethally irradiated B16-MAGEA1 cells (2x10 4 /well, respectively). After incubation for 24 h, the cells were removed, and a biotinylated IFNγ detection antibody was added for 2 h and incubated with streptavidin-alkaline phosphatase for another 1 h at 37˚C. After washing with PBST, the spots were visualized by the addition of the alkaline phosphatase substrate BCIP/NBT and counted using a dissection microscope. The number of MAGEA1-specific T-cell precursors in the splenocytes was calculated by subtracting the IFNγ+ spots of splenocytes on B16-stimulating cells from that on B16-MAGEA1 cells.
ELISA. Irradiated B16-MAGEA1 cells (5x10 5 ) were cocultured with splenocytes (5x10 6 cells) from mice at 2 weeks after the last vaccination, and the cells were cultured in 2 ml of DMEM supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin in 24-well tissue culture plates for 72 h. Murine IL-2 ELSIA kits (Diaclonek, France) were used to assay the presence of IL-2 in the supernatants according to the manufacturer's instructions. The titre of anti-MAGEA1 antibody in the sera was determined as previously described (22).
Tumour treatmente. The mice were s.c. challenged with B16-MAGEA1 tumour cells (1x10 6 cells/mouse, respectively) in the hind legs (D0) as previously described (22) . One week later (day 7), the mice were s.c. vaccinated with 10 µg/100 µl/mouse MB-FP (gas-filled ultrasound microbubbles with HSP70-MAGEA1 fusion protein) in the forelegs. The control groups were s.c. injected with 10 µg/100 µl/mouse HSP70-MAGEA1 fusion protein alone or gas-filled microbubbles alone. Every group included 10 mice. At one week (day 14) and 2 weeks (day 21) later, these mice were boosted with the same regimes. The tumour volumes (length x width 2 x π/6) and weight were measured twice a week after the tumours became palpable and were plotted as the mean tumour volume of the group (means ± SEM) vs. the number of days after the tumour was planted. The survival time of the mice was also recorded.
Tumour challenge experiments. The mice were vaccinated (day 21) with MB-FP, HSP70-MAGEA1 fusion protein or gas-filled microbubbles (10 mice per group), as previously described (12, 13) . At one week (day 14) and 2 weeks later (day 7), the immunization regime was boosted twice. On the 7th day after the last immunization (day 0), the mice were s.c. challenged with B16-MAGEA1 tumour cells (1x10 5 cells/mouse, respectively) in the hind legs. Once the tumours became palpable, observations were taken twice a week, and the ratio of tumour-free mice was recorded.
Statistical analysis. All statistical analyses were carried out using Graphpad Prism 5 software (GraphPad, USA). Results are presented as the means ± SEM. Data were analyzed by one-way analysis of variance (ANOVA) with Tukey's Multiple Comparison test and two-way ANOVA with Bonferroni post-test. Kaplan-Meier survival plots and the log-rank test were used to evaluate differences in animal survival among experimental groups (P-value).
Results

G a s -f i l l e d m i c ro b u b b l e s e f f e c t i ve l y d e l i ve re d HSP70-MAGE-A1 fusion proteins to subcutaneous lymph
nodes. The gas-filled ultrasound microbubbles (MBs) were generated as described in the Methods, and a representative microscopic picture of the MBs is shown in Fig. 1A . The mean diameter of the microbubbles was 6.02 µm, and approximately 90% microbubbles were smaller than 13.86 µm in diameter (Fig. 1B) . Through electrostatic attraction, HSP70-MAGEA1 fusion proteins were easily adsorbed onto the shells of these MBs. Immunoblotting and densitometric analysis indicated that the vast majority of MBs were combined with the HSP70-MAGEA1 fusion protein (Fig. 1C) . The concentration of MBs was approximately 3.2x10 8 /ml, and the protein concentration was approximately 100 µg/ml. Prior to injection, the sample was further diluted with PBS solution (pH=7.4).
As microbubbles are primarily used as ultrasonic contrast agents, we therefore followed the kinetics of MBs persistence in vivo after s.c. injection in the forelegs. Under contrast-enhanced ultrasound-mediated visualization of the low mechanical index ultrasound pulse signal persistence, the MBs were clearly detected in the lymph nodes ( Fig. 2A) . After destroying the MBs with a mechanical index (MI=0.75), the lymph nodes were dissected and the levels of HSP70-MAGEA1 fusion proteins were analysed. The immunoblotting and densitometric results indicated that both HSP70 and MAGEA1 proteins could be detected after immunization. However, the antigens to MAGEA1 were higher in the lymph nodes of mice immunized with MB-FP than in those immunized with FP alone (Fig. 2B) . These results showed that gas-filled ultrasound microbubbles could improve the delivery of HSP70-MAGEA1 antigen to the lymph tissues.
Gas-filled microbubbles could boost the specific immune responses against MAGEA1. CTLs are one of the most important antitumour effectors of the cell immune response in vivo. To determine whether MBs enhanced the cellular immune response, the IFN-γ ELISpot assay was used to determine the number of MAGEA1-specific CD8 + T cells in the splenocytes from mice immunized with gas-filled ultrasound microbubbles (MB), HSP70-MAGEA1 fusion protein (FP) alone and gas-filled ultrasound microbubbles carrying the HSP70-MAGEA1 fusion protein (MB-FP). The results showed that the number of spot-forming T-cell precursors specific to MAGEA1-expressing B16 cells were significantly higher in the splenocytes of mice vaccinated with MB-FP compared with that in mice vaccinated with FP or MB alone (Fig. 3A) . These results suggested that MBs could significantly enhance specific immune responses, although HSP70-MAGEA1 fusion proteins alone also stimulated the generation of INFγ-producing MAGEA1-specific T-cell precursors in vivo. We then analysed the IL-2 secretion of splenocytes in mice treated with various vaccines using ELISA to further determine the T-cell-mediated antitumour immune responses. As shown in Fig. 3B , the IL-2 levels in the supernatant of cocultured irradiated B16-MAGEA1 and splenocytes from mice vaccinated with MB-FP were significantly higher than in the cells from mice vaccinated with FP or MB alone. Combined with the data from ELISpot assay, these results suggested that the gas-filled microbubbles enhanced the generation of MAGEA1-specific cellular immune responses by HSP70-MAGEA1 fusion proteins.
To evaluate the humoural immune responses, the titres of anti-MAGEA1 antibody in the sera of the vaccinated mice were determined using ELISA after the last vaccination. As shown in Fig. 3C , the levels of anti-MAGEA1 antibody were significantly boosted in the mice vaccinated with FP or MB-FP, and the titres of anti-MAGEA1 were slightly higher in mice vaccinated with MB-FP compared with those in mice vaccinated with FP alone. These results indicated that the MB-FP could elicit and boost MAGEA1-specific humoural immune responses (Fig. 3B) . Collectively, these results verified that HSP70-MAGEA1 fusion proteins delivered via gas-filled ultrasound microbubbles could more effectively boost both cellular and humoural immune responses against MAGEA1 compared with the fusion protein alone. 
HSP70-MAGEA1 fusion protein delivered via gas-filled microbubbles delayed tumour growth and prolonged the survival of mice.
To investigate the clinical efficacy of MB-FP and FP vaccines against MAGEA1-expressing tumours, the mice were s.c. inoculated with MAGEA1-expressing B16 (B16-MAGEA1) cells (10 6 cells/mouse) on day 0, and 10 µg/100 µl/mouse of different vaccines was administered on days 7, 14 and 21. The results showed that MB-FP vaccination significantly delayed the growth of B16-MAGEA1 tumours compared with mice vaccinated with FP and MB only (Fig. 4A & B) . Moreover, the survival times of mice with pre-existing B16-MAGEA1 tumours were significantly prolonged after vaccinated with MB-FP compared with mice vaccinated with FP and MB only (Fig. 4C) . These results suggested that the use of gas-filled microbubbles significantly increases the immunoactivity of HSP70-MAGEA1 fusion proteins and improves the survival of mice bearing melanomas, suggesting that MB-FP is a potent and efficient therapeutic vaccine against MAGEA1-expressing tumours.
HSP70-MAGE-A1 fusion protein delivered via gas-filled microbubbles is an efficient protective vaccine against MAGEA1-expressing tumours.
To determine the protective effects of MB-FP vaccines, the mice were vaccinated with MB-FP, MBs and FP as described in the Materials and methods and were then challenged with 1x10 6 B16-MAGEA1 melanoma cells. The mice were monitored for evidence of tumour growth by palpation and inspection. The results showed that MB-FP vaccination slowed the tumour volumes and weight of B16-MAGEA1 cells (Fig. 5A & B) and prolonged the survival times compared with those in the mice vaccinated with FP and MBs alone (Fig. 5C ). In conclusion, these results showed that MB-FP exhibited protective effects against MAGEA1-expressing tumours.
Discussion
As an important member of melanoma antigen, MAGEA1 is expressed in most tumours but not in normal tissues, except testis and ovary. MAGEA1 encodes several antigenic peptides that bind to HLA class I molecules and are recognized by T lymphocytes. To improve the immunoactivity of MAGEA1, several adjuvant molecules have been used. Heat shock protein 70 (HSP70) plays an important role in protein trafficking, folding and antigen presentation. A previous study showed that HSP70 could be exploited to enhance the cellular and humoural immune responses against any attached tumour-specific antigens (TSA) (11) . Moreover, the fusion proteins of HSP70 and TSA have been demonstrated to be powerful strategies to increase immunogenicity (24) (25) (26) . However, a targeted delivery system could effectively increase the immunoactivity and improve the clinical applications of HSP70 fusion proteins. Recently, gas-filled ultrasound microbubbles (MBs) have been used in the clinic as intravenously administered ultrasound-based contrast agents (16, (27) (28) (29) , as microbubbles oscillate and vibrate when a sonic energy field is applied and may reflect ultrasound waves, distinguishing the microbubbles from surrounding tissues. Moreover, gas-filled microbubbles can be used as protein carriers when the shells of microbubbles are composed of special molecules (23, 30, 31) .
Compared with other carriers, the components of gas-filled microbubbles are biodegradable materials, so these compounds do not exhibit immunogenicity, and gas-filled ultrasound microbubbles are small and relatively stable and can remain stable in the body. Moreover, gas-filled ultrasound microbubbles could be broken under ultrasonic irradiation in a targeted area, achieving targeted drug release (32) (33) (34) . In addition, the ultrasound-mediated microbubble destruction could also increase cell membrane permeability, thereby increasing the drug concentration in the target cell. These advantages make gas-filled microbubbles ideal delivery carriers (20, 35) .
Gas-filled microbubbles are used in therapeutic applications based on the intrinsic sonoporation ability of the encapsulated drugs. Microbubbles coupled with ultrasound exposure have been studied for opening the blood-brain barrier (BBB) and delivering drugs (36) (37) (38) . Combining siRNA silencing ABCG2-loaded mPEG-PLGA-PLL nanoparticles and ultrasound-targeted Microbubbles destruction enhanced therapeutic effect of Adriamycin on multidrug-resistant breast cancer (39) . Thrombus-targeting Microbubbles, which have fibrinolytic drugs on the surface reduced the size of the thrombus via ultrasound imaging without prolonging bleeding time (40) .
In the present study, we presented a new strategy for the targeted release of HSP70-MAGEA1 fusion proteins. The proposed polymer gas-filled microbubbles were used as targeted delivery carriers of the fusion protein HSP70-MAGEA1 for subcutaneous delivery around superficial lymph nodes. After the contrast agent into the specific lymph nodes, the gas-filled ultrasound microbubbles carrying the HSP70-MAGEA1 fusion protein released the immunizing antigen, which effectively increased the generation of specific antitumour immune responses.
Consistent with the immune responses, the results of tumour treatment and protection in vivo demonstrated that gas-filled microbubbles could increase the antitumour effects of HSP70-MAGEA1 fusion proteins. Tumour xenografts in mice from B16-MAGE-A1 cells were immunized with MB-FP grew significantly slower compared with those from mice immunized with the HSP70-MAGEA1 fusion protein alone, and the survival times of the mice were significantly prolonged, demonstrating that gas-filled microbubbles could enhance the therapeutic immunization of HSP70-MAGEA1 fusion protein.
Furthermore, we showed that the HSP70-MAGEA1 delivered via gas-filled microbubbles was more proficient at protecting against tumour development when used earlier in the progression of cancer, suggesting the preferential application of this tumour vaccine to prevent tumour recurrence in postoperative cancer patients.
In conclusion, these results showed that the gas-filled microbubble-mediated delivery of HSP70-MAGEA1 fusion protein as a tumour vaccine could be used for targeted release at lymph nodes, thereby effectively improving the antitumour efficacy of the HSP70-MAGEA1 fusion protein. The present study not only described a new strategy for targeted tumour biological treatments using HSP70 fusion proteins but also provided a research basis for controllable drug carriers for clinical application.
